— Know what they know.
Not Investment Advice

LQDA NASDAQ

Liquidia Corporation
1W: +6.0% 1M: +59.3% 3M: +71.6% YTD: +91.0% 1Y: +217.7% 3Y: +715.0% 5Y: +2089.1%
$61.88
+1.90 (+3.17%)
 
Weekly Expected Move ±14.0%
$41 $49 $57 $65 $73
NASDAQ · Healthcare · Biotechnology · Alpha Radar Strong Buy · Power 70 · $5.3B mcap · 62M float · 2.37% daily turnover · Short 42% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$5.3B
52W Range11.85-60.54
Volume1,575,360
Avg Volume1,470,350
Beta0.42
Dividend
Analyst Ratings
6 Buy 0 Hold 1 Sell
Consensus Buy
Company Info
CEORoger A. Jeffs
Employees170
SectorHealthcare
IndustryBiotechnology
IPO Date2018-07-26
419 Davis Drive
Morrisville, NC 27560
US
919 328 4400
About Liquidia Corporation

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Recent Insider Trades

NameTypeSharesPriceDate
JEFFS ROGER S-Sale 25,000 $57.04 2026-05-15
JEFFS ROGER S-Sale 25,000 $58.62 2026-05-14
JEFFS ROGER S-Sale 25,000 $56.29 2026-05-13
JEFFS ROGER S-Sale 25,000 $54.04 2026-05-12
Bloch Stephen M S-Sale 75,801 $48.61 2026-05-11

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms